Literature DB >> 22478724

HER2 TESTS: How Do We Choose?

Bob Carlson.   

Abstract

Incorrect test results defining HER2 status are not uncommon. Getting it wrong leads to spending a fortune on treatment that won't work or denying therapy to people whose lives could be spared by it.

Entities:  

Year:  2008        PMID： 22478724      PMCID： PMC2706184     

Source DB:  PubMed          Journal:  Biotechnol Healthc        ISSN： 1554-169X


  2 in total

1.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

2.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  Arch Pathol Lab Med       Date:  2007       Impact factor: 5.534
  2 in total
  6 in total

1.  Microfluidics-assisted fluorescence in situ hybridization for advantageous human epidermal growth factor receptor 2 assessment in breast cancer.

Authors:  Huu Tuan Nguyen; Raphaël Trouillon; Seiya Matsuoka; Maryse Fiche; Laurence de Leval; Bettina Bisig; Martin Am Gijs
Journal:  Lab Invest       Date:  2016-11-28       Impact factor: 5.662

2.  Fluorescence in situ hybridisation analysis of human epidermal growth factor receptor 2 status for breast cancer cases in Brunei Darussalam.

Authors:  Jessica Pei Chii Kok; Mas Rina Wati Haji Abdul Hamid; Ravi Sekhar Patnaik; Kenneth Yuh Yen Kok
Journal:  Cancer Rep (Hoboken)       Date:  2020-06-08

3.  Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH.

Authors:  Daniel V T Catenacci; Wei-Li Liao; Lei Zhao; Emma Whitcomb; Les Henderson; Emily O'Day; Peng Xu; Sheeno Thyparambil; David Krizman; Kathleen Bengali; Jamar Uzzell; Marlene Darfler; Fabiola Cecchi; Adele Blackler; Yung-Jue Bang; John Hart; Shu-Yuan Xiao; Sang Mee Lee; Jon Burrows; Todd Hembrough
Journal:  Gastric Cancer       Date:  2015-11-18       Impact factor: 7.370

Review 4.  Overview of the CLEOPATRA Trial: Implications for Advanced Practitioners.

Authors:  Karen Herold
Journal:  J Adv Pract Oncol       Date:  2016-01-01

5.  Droplet digital polymerase chain reaction offers an improvisation over conventional immunohistochemistry and fluorescent in situ hybridization for ascertaining Her2 status of breast cancer.

Authors:  Moushumi Suryavanshi; Jiten Jaipuria; Anurag Mehta; Dushyant Kumar; Manoj Kumar Panigrahi; Haristuti Verma; Mumtaz Saifi; Sanjeev Sharma; Simran Tandon; Dinesh Chandra Doval; Bhudev C Das
Journal:  South Asian J Cancer       Date:  2019 Oct-Dec

Review 6.  FISH and chips: a review of microfluidic platforms for FISH analysis.

Authors:  Pablo Rodriguez-Mateos; Nuno Filipe Azevedo; Carina Almeida; Nicole Pamme
Journal:  Med Microbiol Immunol       Date:  2020-01-21       Impact factor: 3.402
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.